Modified Delphi for Genomic Bereavement Care

Status Completed

Clinical Trial Summary

It is estimated that 1 in 4 pregnancies end in loss, be these early miscarriages, ectopic pregnancies, or later intrauterine losses for any reason. Genomics is a major part of pregnancy loss, and clinicians want to offer the best and most appropriate test available to women and their families, whilst ensuring that there is equity in the access to this testing, so that no family goes through a loss without the right support and information. Whilst there is limited information to inform professionals as to how to incorporate genomics into bereavement care there is a need to identify current expert consensus as to how this should be performed, in order to make recommendations for best practice.

Clinical Trial Description

There is a lack of guidance available as to how to care for women and families who suffer a pregnancy loss where fetal anomalies have been found and a genetic cause is suspected. As it is estimated that 1 in 4 pregnancies end in loss, these families make up a significant proportion of the population that maternity services care for and with no consensus in this area many families may have a poor experience. As the field of genomics rapidly advances, it is important that patient care reflects the changes in practice and that the most appropriate tests and support are offered. All aspects of patient care will be reviewed including diagnosis, delivery, laboratory investigations, postnatal care and follow up in future pregnancies. The role of the genomics midwife will be explored and the role of the bereavement midwife will be further defined when it comes to support following pregnancy loss where there is likely an underlying genomic cause. The aim of this modified delphi study is to understand what the current expert consensus is for genomic bereavement care. Using this, best practice guidance will be written that can be used within the NHS to better support families who suffer pregnancy loss during this pregnancy and in the future. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05655741
Study type	Observational
Source	The Leeds Teaching Hospitals NHS Trust
Contact
Status	Completed
Phase
Start date	October 28, 2022
Completion date	March 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03548779` - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2	N/A
Completed	`NCT03292302` - Phase 1 Study of ELX-02 in Healthy Adults	Phase 1
Withdrawn	`NCT03658382` - Virtual Visits for Results Disclosure	N/A
Recruiting	`NCT02266615` - Biobank Clinical Genetics Maastricht (KG01)
Recruiting	`NCT02450851` - Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network
Recruiting	`NCT05472714` - Educational Video for Genetic Testing	N/A
Recruiting	`NCT04285814` - Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood
Completed	`NCT05443113` - Young Pectus Excavatum Patients and Genetic Defects
Completed	`NCT03847909` - A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2	Phase 2
Completed	`NCT04584528` - Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease	N/A
Not yet recruiting	`NCT06048523` - Prospective Cohort Study of Neurogenetic Diseases	N/A
Completed	`NCT02225522` - Genomic Sequencing in Acutely Ill Neonates	N/A
Enrolling by invitation	`NCT06089954` - Penn Medicine Biobank Return of Results Program	N/A
Completed	`NCT03713333` - Implementing Digital Health in a Learning Health System	N/A
Completed	`NCT03309605` - Phase 1 Study of ELX-02 in Healthy Adult Subjects	Phase 1
Recruiting	`NCT05499091` - Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN	N/A
Completed	`NCT04556487` - Turkish Affordances in the Home Environment for Motor Development-Infant Scale (AHEMD-IS)
Completed	`NCT04556500` - Turkish Version of the Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)
Recruiting	`NCT02551081` - Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units
Active, not recruiting	`NCT05049967` - iKnow: A Prospective Study to Evaluate the Use of Multi-omics in Multi-System, Early Onset Disorders

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.